Table 1.
Clinical and demographic features of the 20 patients with diffuse systemic sclerosis
| Sex/age (yr) | Disease duration at skin biopsy (yr from RP) | mRSS/score at skin biopsy | Autoantibodies | ILD | PAH | SRC | RP | DU |
|---|---|---|---|---|---|---|---|---|
| 95% F | 50% EOS 50% LSS |
100% ANA/Scl70 | 25% ILD | 15% PAH; | 0% SCR | 100% RP | 30% DU | |
| F/45 | < 1 | 10/2 | ANA/Scl-70 | No | No | No | Yes | No |
| F/22 | < 1 | 13/1 | ANA/Scl-70 | No | No | No | Yes | Yes |
| F/31 | < 1 | 08/2 | ANA/Scl-70 | No | No | No | Yes | No |
| F/38 | < 1 | 09/2 | ANA/Scl-70 | No | Yes | No | Yes | Yes |
| M/20 | < 1 | 11/1 | ANA/Scl-70 | No | No | No | Yes | No |
| F/40 | < 1 | 10/2 | ANA/Scl-70 | No | No | No | Yes | No |
| F/31 | < 1 | 10/1 | ANA/Scl-70 | No | No | No | Yes | No |
| F/21 | < 1 | 09/1 | ANA/Scl-70 | No | No | No | Yes | No |
| F/31 | < 1 | 14/1 | ANA/Scl-70 | No | No | No | Yes | No |
| F/42 | < 1 | 16/2 | ANA/Scl-70 | Yes | No | No | Yes | No |
| F/45 | 4 | 17/2 | ANA/Scl-70 | No | No | No | Yes | No |
| F/21 | 5 | 15/1 | ANA/Scl-70 | No | No | No | Yes | No |
| F/30 | 6 | 18/2 | ANA/Scl-70 | No | Yes | No | Yes | Yes |
| F/33 | 4 | 13/2 | ANA/Scl-70 | Yes | No | No | Yes | No |
| F/34 | 4 | 12/1 | ANA/Scl-70 | No | No | No | Yes | Yes |
| F/40 | 4 | 10/2 | ANA/Scl-70 | Yes | Yes | No | Yes | No |
| M/26 | 6 | 10/2 | ANA/Scl-70 | Yes | No | No | Yes | Yes |
| F/21 | 4 | 11/1 | ANA/Scl-70 | No | No | No | Yes | No |
| F/30 | 3 | 12/2 | ANA/Scl-70 | Yes | No | No | Yes | Yes |
| F/33 | 4 | 12/1 | ANA/Scl-70 | No | No | No | Yes | No |
Abbreviations: EOS Early-onset subset, LSS Long-standing subset, RP Raynaud’s phenomenon, mRSS Modified Rodnan skin score (maximum possible score 51), ILD Interstitial lung disease, ANA Antinuclear antibodies, Scl-70 Antitopoisomerase, PAH Pulmonary arterial hypertension, SRC Scleroderma renal crisis, DU Digital ulcers
The internal organ involvement is referred to the time of biopsies